MOTS, US62014P5044

Motus GI presents Pure-Vu system: what it means for Motus GI stock

Published on 10/06/2026 at 01:05 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Pure-Vu targets colonoscopy and upper endoscopy procedures. Motus GI stock has a November 17, 2026 earnings date.

MOTS, US62014P5044, Illustration mit AI erstellt.

Motus GI Holdings, Inc. (ISIN US62014P5044) presents the Pure-Vu system as a medical device for improving visualization during colonoscopy and upper gastrointestinal endoscopy. Motus GI describes the system as a tool intended to improve procedure quality and efficiency.

Pure-Vu targets endoscopy quality

The company website highlights colonoscopy and upper endoscopy as the two principal applications. Its product presentation centers on visualization, a key operational issue when blood, clots or other debris affect the endoscopist's view during a procedure.

Motus GI's profile is concentrated around one technology platform rather than a broad medical-device portfolio. That concentration makes product adoption, clinical use and the future ownership of the technology central issues for the listed entity.

Historical revenue shows contraction

Canli Capital records historical fiscal 2023 revenue of USD 319,000, compared with USD 592,000 in fiscal 2022, a decline of 46.11 percent. The same record identifies fiscal 2023 as the latest annual period in that selected history.

The available financial statement data also show historical fiscal Q1 2024 revenue of USD 64,000 and a net loss of USD 2.11 million. The revenue figure was far below the USD 319,000 reported for fiscal 2023, but the periods are not directly comparable because one covers a quarter and the other a full year.

Trading range and next date

The Nasdaq OTC Other record dated October 2, 2026 lists a 52-week range from USD 0.000001 to USD 0.10. The spread between those levels illustrates the extreme historical range of the security rather than a current valuation signal.

Forecaster lists November 17, 2026 as the next earnings date. That date gives the market a concrete point for a future corporate update, while the latest filing record captured by Canli Capital ends with a fiscal Q1 2024 report filed on May 14, 2024.

Motus GI remains a specialized listing

Motus GI operates in the medical-device sector and is associated with the Pure-Vu system. The combination of a narrow product focus, historical losses and a wide recorded trading range leaves future company updates especially important for interpreting the listed security.